1.26
-0.02 (-1.56%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Biodesix, Inc. | Mixed | Bearish |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Birchview Capital, Lp | 31 Dec 2023 | 5,193,336 |
| 52 Weeks Range |
1.03 - 2.21
|
|
| High | 3.50 (Canaccord Genuity, 177.78%) | Buy |
| Median | 3.50 (177.78%) | |
| Average | 3.50 (177.78%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 04 Mar 2024 | 3.50 (177.78%) | Buy | 1.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2024 | Announcement | Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 |
| 09 Apr 2024 | Announcement | Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting |
| 05 Apr 2024 | Announcement | Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement |
| 25 Mar 2024 | Announcement | Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center |
| 01 Mar 2024 | Announcement | Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights |
| 26 Feb 2024 | Announcement | Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference |
| 16 Feb 2024 | Announcement | Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |